A practical reference on WADA: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
=== Lycopene === Lycopene is a key intermediate in the biosynthesis of beta-carotene and xanthophylls. Lycopene may be the most powerful carotenoid quencher of singlet oxygen. Due to its strong color and non-toxicity, lycopene is a useful food coloring (registered as E160d) and is approved for usage in the US, Australia and New Zealand (registered as 160d) and the EU.
Phillips and Connelly had an agreement that distribution of MET-Rx would be controlled, and that they would not sell it to retail outlets in order to keep supply low during the period of high demand created by the advertisements in Muscle Media 2000. Connelly however, had other ideas and began selling it to mainstream distributors and department stores. Phillips believed this move lessened its appeal to bodybuilders, and destroyed the "mystique" of the product. The two parted ways, and as part of the settlement, Phillips was legally bound not to mention the name of MET-Rx in his magazines (thereafter he would refer to it as "the leading brand"). But by then Phillips had his eye on another venture that would eclipse MET-Rx altogether – EAS.
TFEU article 49 says states are exempt from infringing others' freedom of establishment when they exercise "official authority". But regulation of an advocate's work (as opposed to a court's) was not official. By contrast in Commission v Italy the Court of Justice held that a requirement for lawyers in Italy to comply with maximum tariffs unless there was an agreement with a client was not a restriction. The Grand Chamber of the Court of Justice held the commission had not proven that this had any object or effect of limiting practitioners from entering the market. Therefore, there was no prima facie infringement freedom of establishment that needed to be justified.
Sources: en.wikipedia.org
For example, they are known to use both wine and raki in their ceremonial meetings, and were not known, in earlier times, to have observed the fast of Ramadan or the obligation of five daily prayer times. (ref: "Conforming Haji Bektash: A Saint and His Followers between Orthopraxy and Heteropraxy"; Mark Soileau, Die Welt des Islams 54 (2014) 423-459) Bektashis follow the modern-day Bektashi Dedebabate, currently headed by Baba Mondi. Bektashis consider the Dedebaba as leader over the entire branch. Bektashism is also heavily permeated with Shia Islamic concepts, such as the marked reverence of Ali, the Twelve Imams, and the ritual commemoration of Ashura marking the Battle of Karbala. The old Persian holiday of Nowruz is celebrated by Bektashis as Ali's birthday (see also Nevruz in Albania). The Bektashi order is a Sufi order and shares much in common with other Islamic mystical movements, such as the need for an experienced spiritual guide—called a baba in Bektashi parlance—as well as the Sufi doctrine of "the four gates that must be traversed": Sharī'a (religious law), Ṭarīqa (the spiritual path), Ma'rifa (true knowledge), and Ḥaqīqa (truth). There are many other practices and ceremonies that share similarities with other faiths, such as a ritual meal (muhabbet) and yearly confession of sins to a baba (magfirat-i zunub مغفرة الذنوب). Bektashis base their practices and rituals on their non-orthodox and mystical interpretation and understanding of the Quran and the prophetic practice (Sunnah).
Historically, men's pain has been treated as abnormal and requiring medical intervention, while women's pain, especially related to menstruation and childbirth, was considered normal and often left untreated. The perception of menstruation-related pain as natural—sometimes reinforced by religious narratives—contributed to this neglect. Pain relief in childbirth gradually advanced, with chemical anesthesia introduced in the 19th century, and techniques such as pain-free childbirth in 1950s France. Epidural anesthesia became common from the 1980s onward. Menstrual pain and conditions like endometriosis (affecting around 10% of women) have only been widely recognized by the medical profession since the late 2010s. Endometriosis was officially recognized as a medical condition in France in 1990. A national awareness plan was launched in 2019, and the disease was classified as a long-term illness in 2022. Some studies suggest that women may delay seeking care, often prioritizing family responsibilities and underestimating their symptoms.
On July, the Ministry of Education announced that the federal programme for creation of civic-military schools would be stopped, and that each state would have the option to keep or extinguish the programme. On the same month, Lula also signed in the Education Ministry's "full-time school program" after modifications to the original project, which dealt with increasing government investments in these schools, as well as reforming many part-time ones to also allow for the offering of these options, were approved by the Chamber of Deputies. On 6 November 2023, education minister Camilo Santana announced that people with FIES debts could now renegotiate them with the federal government, the attitude is similar to the Desenrola Brasil programme, also created during the Lula government in an effort to reduce indebtedness among the people, especially those of lower classes. The government announced on 12 March 2024 the construction of 100 new Federal Institutes of Education, Science and Technology in all federative units in Brazil by 2026. The ministry of education announced that it would be Investing ~R$3.9 billion in the construction of these units, with the funds being made possible through the New PAC. The government estimates the creation of 140 thousand new enrollments, the majority in technical courses integrated into secondary education (high school). The region that will receive the most Institutes will be the Northeast, with 38 new units planned, while the State that will receive the largest number of Institutes will be São Paulo, with 12 new units.
Sources: en.wikipedia.org
In 2001, Nakai et al. reported the development of GCaMP1 as a Ca2+ probe with improved signal-to-noise ratio compared to previously developed fluorescent Ca2+ probes. The first transgenic mouse expressing GCaMP1 was reported in 2004. However, at 37 ˚C (physiological temperature in mammals), GCaMP1 did not fold stably or fluoresce, limiting its potential use as a calcium indicator in vivo. In 2006, Tallini et al. subsequently reported the improvement of GCaMP1 to GCaMP2, which exhibited brighter fluorescence than GCaMP1 and greater stability at mammalian body temperatures. Tallini et al. expressed GCaMP2 in cardiomyocytes in mouse embryos to perform the first in vivo GCaMP imaging of Ca2+ in mammals. Further modifications of GCaMP, including GCaMP3, GCaMP5, GCaMP6, and jGCaMP7, have been developed to progressively improve the signal, sensitivity, and dynamic range of Ca2+ detection, with recent versions exhibiting fluorescence similar to native GFP.
The protein content of C. vulgaris varies from 42 to 58% of its biomass dry weight. These proteins are considered as having a good nutritional quality compared to the standard profile for human nutrition of the World Health Organization and Food and Agriculture Organization, as the algae synthesizes amino acids. The algae also contains lipids (5–40% of the dry mass), carbohydrates (12–55% dry weight), and pigments including chlorophyll, reaching 1–2 % of the dry weight. Containing dietary minerals and vitamins, C. vulgaris is marketed as a dietary supplement, food additive, or food colorant. Extracted proteins have been investigated for manufacturing of emulsion and foams. It is not widely incorporated in food products due to its dark green color and smell similar to that of fish. As a dietary supplement, it may be sold as capsules, extracts, tablets or powder. Vitamin B12, specifically in the form of methylcobalamin, has been identified in Chlorella vulgaris.
Vantin (by Pfizer) in suspension or tablet form. Toraxim (by Delta Pharma Ltd., Bangladesh) Trucef (by Renata Limited, Bangladesh) Tricef (by Alkaloid Skopje, North Macedonia) Orelox (by Sanofi-Aventis) MAPDOX-CV: Combination cefpodoxime–clavulanic acid MONOTAX O (cefpodoxime)/MONOTAX CV (cefpodoxime–clavulanic acid) by Zydus Healthcare Ltd. ACXIME 200/CV (by Allencia Biosciences, India) POSTPOD-50 (cefpodoxime 50mg/5ml) by Laafon Galaxy Pharmaceuticals
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.